BioVie BIVI 深 沪
已收盘 10-30 16:00:00 美东时间
1.43
+0.050
+3.62%
华盛通- 最 高1.49
- 今 开1.39
- 成交量 10.58万股
- 最 低 1.38
- 昨 收 1.38
- 总市值 1241.63万
- 52周最高 3.79
- 市盈率 静 --
- 换手率 1.22%
- 52周最低 0.82
- 委 比 -58.30%
- 总股本 868.27万
- 历史最高 4609.80
- 量 比 0.84
- 振 幅 7.97%
- 历史最低 0.82
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
BioVie Inc. has been invited to present at the 2026 RECOVER-TLC Workshop, where Dr. Penelope Markham will share results from the Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID's neurological symptoms. The trial showed consistent improvement trends in fatigue, post-exertional malaise, and cognitive impairment, particularly in patients with severe baseline symptoms. Bezisterim demonstrated a favorable safety profile. The RECOVER-TLC ...
10-26 12:00
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie Inc. announced that two abstracts from its ADDRESS-LC Phase 2 trial for Long COVID and SUNRISE-PD Phase 2 trial for Parkinson’s Disease have been accepted for presentation at ANA2026 in San Diego, October 17-20, 2026. The studies will be presented as posters. Bezisterim (NE3107), the company’s investigational drug, targets neuroinflammation and insulin resistance, showing potential benefits in reducing inflammation and improving symptoms i...
10-14 12:00
BioVie’s NE3107 Long COVID Trial Completion: What Investors Should Watch Next
Biovie Inc. ($BIVI) announced an update on their ongoing clinical study. BioVie...
09-23 00:30
What's Going On With BioVie Stock on Tuesday?
Clinical-stage biopharmaceutical firm BioVie Inc. (NASDAQ:BIVI) stock is trading lower after the company shared topline results from its Phase 2 ADDRESS-LC study evaluating bezisterim in Long COVID patients. Pre-specified subgroup analyses submitted to the FDA before unblinding showed that participa...
09-16 00:21
BioVie Enters Sales Agreement With Alliance Global Partners For Up To $6,464,341 Of Stock
On September 11, 2026, BioVie Inc., a Nevada corporation (the "Company"), entered into a sales agreement (the "Sales Agreement") with A.G.P./Alliance Global Partners (the "Agent"), pursuant to which the Company may issue and sell from time to time, to or through the Agent, shares of the Company’s Cl...
09-14 18:13
宝莱特新注册《BioView C100系列麻醉视频喉镜主控软件V1.0》项目的软件著作权
证券之星消息，近日宝莱特（300246）新注册了《BioView C100系列麻醉视频喉镜主控软件V1.0》项目的软件著作权。今年以来宝莱特新注册软件著作权9个。
09-09 04:25
BioVie shares are trading higher after the company announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
BioVie shares are trading higher after the company announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
08-31 23:29
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Inc. has completed the last patient visit for its ADDRESS-LC Phase 2 trial evaluating bezisterim for treating Long COVID neurological symptoms. Topline results are expected by September 2026. The study, funded by a $13.13 million grant from the U.S. Department of War, aims to assess bezisterim's efficacy in reducing symptoms like fatigue and brain fog. Bezisterim, an investigational drug targeting neuroinflammation, has shown promise in Pa...
08-31 12:00
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Webull Corp (NASDAQ:BULL) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Benzinga Pro. The brokerage platform ...
08-20 16:53
